Alwin Capital’s New Dual-Currency Fund Closed and Exceeded Fundraising Target
BEIJING, Oct. 25, 2022 /PRNewswire/ -- Alwin Capital recently closed a new dual-currency fund, raising over US$300 million, which exceeds their fundraising target. The RMB investors of this new dual-currency fund include large FoFs, Chinese government guidance funds, leading companies in medical industry, insurance companies, banks, and other financial institutions in China. Based...
Metabolon Advances the Understanding of Inflammation and Inflammatory Response with New Oxysterols Targeted Panel
The new targeted metabolomics panel provides absolute quantitation for important bioactive intermediaries of inflammation and disease pathogenesis MORRISVILLE, N.C., Oct. 25, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch...
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil. could be made available for late-stage development. SK bioscience to secure new vaccines and establish pandemic response system SK bioscience to enhance human health by successfully developing innovative vaccines with global partnership SEOUL, South...
FDA Accepts NMP’s Clinical Trial Application for Development of NMK89 as Imaging Agent for Cancer Diagnosis
- Clinical Study Set to Begin, Focusing on Diagnostic Use of Theranostics - TOKYO, Oct. 25, 2022 /PRNewswire/ -- Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, is pleased to announce that the U.S. Food and Drug Administration (FDA) has recently accepted NMP's Investigational New Drug (IND) application to initiate a first-in-human phase I clinical...
Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report
Report analyzes benefits, financing, R&D activity and more to reveal emerging standouts in medical science United States and Mainland China at the forefront of RNA technology advancement LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced...
MAINTAIN HEALTH WITH HERBALMEDS BY BiO-LiFE NATURAL WELLNESS RANGE OF PRODUCTS
Support Your Wellness with Natural Herbal Medicines KUALA LUMPUR, Malaysia, Oct. 25, 2022 /PRNewswire/ -- BiO-LiFE, one of Malaysia's leading healthcare companies with a range of quality health products based on scientific testing, is now offering natural products for those looking for natural, herbal solutions for their relief. Herbalmeds range of products by BiO-LiFE...
BioCell Technology Expands Global Presence and Trust with Prestigious Halal Certification
BioCell Collagen®, the company's flagship ingredient, is now halal-certified by the Islamic Information Documentation and Certification GmbH (IIDC), an accreditation accepted in nearly all Islamic countries IRVINE, Calif., Oct. 25, 2022 /PRNewswire/ -- BioCell Collagen®, a clinically-studied dietary supplement ingredient with more than twenty years of safe and effective use, is now recognized...
MiRXES collaborates with Plug and Play to launch Southeast Asia’s first science-backed commercialization engine and validator program
MiRXES Translator Program will accelerate revenue growth of start-ups and importantly, adoption of preventive healthcare solutions globally SINGAPORE, Oct. 25, 2022 /PRNewswire/ -- MiRXES, a Singapore-headquartered biotechnology company focused on saving lives and improving health economics and outcomes through RNA-powered disease early detection and precision genomic tests, today launched the first edition of MiRXES Translator Program, Southeast Asia's first business...
MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval
GENEVA, Oct. 25, 2022 /PRNewswire/ -- Following our communication last week "MedAlliance to be acquired by Cordis", MedAlliance is pleased to make the following announcement: SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal clinical trial. This is...
T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness
Preclinical data showing how ERA™, eTurna™ technologies turbocharge T-cell therapies presented at New Frontiers of RNA Nanotherapeutics meeting today ERA™ boosts CAR T-cell efficacy by overcoming T-cell exhaustion that inhibits cancer cures eTurna™ delivery platform delivers more healthy, functional T-cells than electroporation, without the safety risks of viral vectors Use of both technologies has the potential to lower...
